CA
BMRN icon

Continental Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Continental Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,000
Closed -$1.37M – 141
2015
Q1 		$1.37M Hold
11,000
– – 0.3% 98
2014
Q4 		$994K Buy
+11,000
New +$915K 0.2% 113

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Continental Advisors's BMRN Position: Q1 2015 in Review

Continental Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 900 shares — an estimated $95.4K sold.

Continental Advisors first reported a position in BMRN in Q4 2014 and held it in 1 quarter. The position peaked at $81K in Q4 2014. 377 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

  • Continental Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Continental Advisors sold 900 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $95.4K.
  • Continental Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Continental Advisors's BioMarin Pharmaceuticals position peaked at $81K in Q4 2014.
  • 377 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Continental Advisors's 13F filing for Q1 2015, filed 15 May 2015.